Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2022-03-07 02:49:00 UTC |
---|
HMDB ID | HMDB0000234 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Testosterone |
---|
Description | Testosterone is the primary male sex hormone and anabolic steroid from the androstane class of steroids. It is the most important androgen in potency and quantity for vertebrates. In humans, testosterone plays a key role in the development of male reproductive tissues such as testes and prostate, as well as promoting secondary sexual characteristics such as increased muscle and bone mass, and the growth of body hair. In addition, testosterone is involved in health and well-being, and the prevention of osteoporosis. Testosterone exerts its action through binding to and activation of the androgen receptor. In mammals, testosterone is metabolized mainly in the liver. Approximately 50% of testosterone is metabolized via conjugation into testosterone glucuronide and to a lesser extent testosterone sulfate by glucuronosyltransferases and sulfotransferases. An additional 40% of testosterone is metabolized in equal proportions into the 17-ketosteroids androsterone and etiocholanolone via the combined actions of 5alpha- and 5beta-reductases, 3alpha-hydroxysteroid dehydrogenase, and 17beta-HSD. Like other steroid hormones, testosterone is derived from cholesterol. The first step in the biosynthesis of testosterone involves the oxidative cleavage of the side-chain of cholesterol by the cholesterol side-chain cleavage enzyme (P450scc, CYP11A1) to give pregnenolone. In the next step, two additional carbon atoms are removed by the CYP17A1 (17alpha-hydroxylase/17,20-lyase) enzyme to yield a variety of C19 steroids. In addition, the 3beta-hydroxyl group is oxidized by 3beta-hydroxysteroid dehydrogenase to produce androstenedione. In the final and rate limiting step, the C17 keto group androstenedione is reduced by 17beta-hydroxysteroid hydrogenase to yield testosterone. Testosterone is synthesized and released by the Leydig cells in the testes that lie between the tubules and comprise less than 5% of the total testicular volume. Testosterone diffuses into the seminiferous tubules where it is essential for maintaining spermatogenesis. Some testosterone binds to an androgen-binding protein (ABP) that is produced by the Sertoli cells and is homologous to the sex-hormone binding globulin that transports testosterone in the general circulation. The ABP carries testosterone in the testicular fluid where it maintains the activity of the accessory sex glands and may also help to retain testosterone within the tubule and bind excess free hormone. Some testosterone is converted to estradiol by Sertoli cell-derived aromatase enzyme. Leydig cell steroidogenesis is controlled primarily by luteinizing hormone with negative feedback of testosterone on the hypothalamic-pituitary axis. The requirement of spermatogenesis for high local concentrations of testosterone means that loss of androgen production is likely to be accompanied by loss of spermatogenesis. Indeed, if testicular androgen production is inhibited by the administration of exogenous androgens then spermatogenesis ceases. This is the basis of using exogenous testosterone as a male contraceptive. The largest amounts of testosterone (>95%) are produced by the testes in men, while the adrenal glands account for most of the remainder. Testosterone is also synthesized in far smaller total quantities in women by the adrenal glands, thecal cells of the ovaries, and, during pregnancy, by the placenta. Testosterone levels fall by about 1% each year in men. Therefore, with increasing longevity and the aging of the population, the number of older men with testosterone deficiency will increase substantially over the next several decades. Serum testosterone levels decrease progressively in aging men, but the rate and magnitude of decrease vary considerably. Approximately 1% of healthy young men have total serum testosterone levels below normal; in contrast, approximately 20% of healthy men over age 60 years have serum testosterone levels below normal. (PMID: 17904450 , 17875487 ). |
---|
Structure | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1 |
---|
Synonyms | Value | Source |
---|
17beta-Hydroxy-4-androsten-3-one | ChEBI | 4-Androsten-17beta-ol-3-one | ChEBI | Androderm | ChEBI | Testosteron | ChEBI | Testosterona | ChEBI | Testosteronum | ChEBI | Androgel | Kegg | Axiron | Kegg | Striant | Kegg | Testim | Kegg | 17b-Hydroxy-4-androsten-3-one | Generator | 17Β-hydroxy-4-androsten-3-one | Generator | 4-Androsten-17b-ol-3-one | Generator | 4-Androsten-17β-ol-3-one | Generator | (+)-Testosterone | HMDB | (+-)-8-Iso-testosterone | HMDB | (+-)-Retrotestosterone | HMDB | (+-)-Testosterone | HMDB | (17b)-17-Hydroxy-androst-4-en-3-one | HMDB | 13-Iso-testosterone | HMDB | 17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one | HMDB | 17-Hydroxy-androst-4-en-3-one | HMDB | 17-Hydroxy-D4-androsten-3-one | HMDB | 17a-Hydroxy-(13a)-androst-4-en-3-one | HMDB | 17a-Hydroxy-13a-androst-4-en-3-one | HMDB | 17a-Hydroxy-14b-androst-4-en-3-one | HMDB | 17a-Hydroxy-androst-4-en-3-one | HMDB | 17b-Hydroxy-(10a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(13a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(8a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(8a,10a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(9b)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(9b,10a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-13a-androst-4-en-3-one | HMDB | 17b-Hydroxy-8a-androst-4-en-3-one | HMDB | 17b-Hydroxy-androst-4-en-3-ON | HMDB | 17b-Hydroxy-androst-4-en-3-one | HMDB | 17b-Hydroxy-D4-androsten-3-one | HMDB | 17b-Hydroxyandrost-4-en-3-one | HMDB | 17b-Hydroxyandrost-4-ene-3-one | HMDB | 17b-Testosterone | HMDB | 4-Androsten-3-one-17b-ol | HMDB | 8-Iso-testosterone | HMDB | 9b,10a-Testosterone | HMDB | 9b-Testosterone | HMDB | Androlin | HMDB | Andronaq | HMDB | Andropatch | HMDB | Androst-4-en-17b-ol-3-one | HMDB | Androst-4-ene-17b-ol-3-one | HMDB | Andrusol | HMDB | Cristerona T | HMDB | D4-Androsten-17b-ol-3-one | HMDB | Epitestosteron | HMDB | Geno-cristaux gremy | HMDB | Homosteron | HMDB | Homosterone | HMDB | Lumitestosteron | HMDB | Mertestate | HMDB | Neotestis | HMDB | Oreton | HMDB | Orquisteron | HMDB | Perandren | HMDB | Percutacrine androgenique | HMDB | Primotest | HMDB | Primoteston | HMDB | rac-17b-Hydroxy-(13a)androst-4-en-3-one | HMDB | rac-17b-Hydroxy-(8a)-androst-4-en-3-one | HMDB | rac-17b-Hydroxy-(9b,10a)androst-4-en-3-one | HMDB | rac-17b-Hydroxy-androst-4-en-3-one | HMDB | Relibra | HMDB | Retrotestosterone | HMDB | Sustanon | HMDB | Sustanone | HMDB | Sustason 250 | HMDB | Synandrol F | HMDB | Teslen | HMDB | Testandrone | HMDB | Testiculosterone | HMDB | Testobase | HMDB | Testoderm | HMDB | Testogel | HMDB | Testolent | HMDB | Testolin | HMDB | Testopropon | HMDB | Testosteroid | HMDB | Testoviron schering | HMDB | Testoviron T | HMDB | Testro aq | HMDB | Testrone | HMDB | Testryl | HMDB | Tostrelle | HMDB | Tostrex | HMDB | Viatrel | HMDB | Virormone | HMDB | Virosterone | HMDB | Androtop | HMDB | CEPA brand OF testosterone | HMDB | Histerone | HMDB | SmithKline beecham brand OF testosterone | HMDB | Solvay brand OF testosterone | HMDB | Sterotate | HMDB | 17-beta-Hydroxy-8 alpha-4-androsten-3-one | HMDB | AstraZeneca brand OF testosterone | HMDB | Bartor brand OF testosterone | HMDB | Dr. kade brand OF testosterone | HMDB | Ferring brand OF testosterone | HMDB | Hauck brand OF testosterone | HMDB | Pasadena brand OF testosterone | HMDB | Testosterone sulfate | HMDB | Ulmer brand OF testosterone | HMDB | Unimed brand OF testosterone | HMDB | Watson brand OF testosterone | HMDB | 17-beta-Hydroxy-4-androsten-3-one | HMDB | 8 Isotestosterone | HMDB | 8-Isotestosterone | HMDB | Auxilium pharmaceuticals inc. brand OF testosterone | HMDB | Faulding brand OF testosterone | HMDB | Paladin brand OF testosterone | HMDB | Schering brand OF testosterone | HMDB | 17 beta Hydroxy 4 androsten 3 one | HMDB | 17 beta Hydroxy 8 alpha 4 androsten 3 one | HMDB | GlaxoSmithKline brand OF testosterone | HMDB | Ortho brand OF testosterone | HMDB | Testopel | HMDB |
|
---|
Chemical Formula | C19H28O2 |
---|
Average Molecular Weight | 288.4244 |
---|
Monoisotopic Molecular Weight | 288.20893014 |
---|
IUPAC Name | (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
---|
Traditional Name | (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
---|
CAS Registry Number | 58-22-0 |
---|
SMILES | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1 |
---|
InChI Key | MUMGGOZAMZWBJJ-DYKIIFRCSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- 3-oxo-delta-4-steroid
- 3-oxosteroid
- Hydroxysteroid
- Oxosteroid
- 17-hydroxysteroid
- Delta-4-steroid
- Cyclohexenone
- Cyclic alcohol
- Secondary alcohol
- Ketone
- Cyclic ketone
- Organooxygen compound
- Alcohol
- Carbonyl group
- Organic oxygen compound
- Hydrocarbon derivative
- Organic oxide
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 155 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.023 mg/mL | Not Available | LogP | 3.32 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Testosterone,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O[Si](C)(C)C | 2764.5 | Semi standard non polar | 33892256 | Testosterone,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CC[C@@H]2O | 2636.1 | Semi standard non polar | 33892256 | Testosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CC[C@@H]2O[Si](C)(C)C | 2694.5 | Semi standard non polar | 33892256 | Testosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CC[C@@H]2O[Si](C)(C)C | 2693.2 | Standard non polar | 33892256 | Testosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CC[C@@H]2O[Si](C)(C)C | 2974.7 | Standard polar | 33892256 | Testosterone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C | 3021.3 | Semi standard non polar | 33892256 | Testosterone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CC[C@H](O)[C@@]3(C)CC[C@@H]12 | 2917.7 | Semi standard non polar | 33892256 | Testosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]3(C)CC[C@@H]12 | 3233.8 | Semi standard non polar | 33892256 | Testosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]3(C)CC[C@@H]12 | 3170.2 | Standard non polar | 33892256 | Testosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]3(C)CC[C@@H]12 | 3231.9 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Testosterone GC-MS (1 TMS) | splash10-004i-3910000000-d6ace9b7f8aff4dd46d0 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone GC-MS (2 TMS) | splash10-053u-1920200000-db3504f562c54e6e1bbb | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone GC-MS (1 MEOX; 1 TMS) | splash10-004l-3910000000-b43cd1ee268a855c8aa0 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone GC-MS (1 MEOX; 1 TMS) | splash10-004l-3910000000-356ddfa8ddf8e551278d | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone EI-B (Non-derivatized) | splash10-0597-7920000000-dde7fba02fcbcec2d665 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone EI-B (Non-derivatized) | splash10-05fs-4920000000-ccd839134de79f179f9e | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone EI-B (Non-derivatized) | splash10-00ds-0950000000-c65fc8043083ad93d169 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone GC-MS (Non-derivatized) | splash10-004i-3910000000-d6ace9b7f8aff4dd46d0 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone GC-MS (Non-derivatized) | splash10-053u-1920200000-db3504f562c54e6e1bbb | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone GC-MS (Non-derivatized) | splash10-004l-3910000000-b43cd1ee268a855c8aa0 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Testosterone GC-MS (Non-derivatized) | splash10-004l-3910000000-356ddfa8ddf8e551278d | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone GC-MS (Non-derivatized) - 70eV, Positive | splash10-074i-0390000000-09e2a725ebd92c93dc88 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone GC-MS (1 TMS) - 70eV, Positive | splash10-001j-3349000000-75c3f3e0341bb42eb819 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-00dv-5940000000-5e22fba0c369374c75df | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-000i-0090000000-914b212f1dbb7fb7b1ac | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-052b-9800000000-d2e38d44d2f16d0a4203 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-052b-9300000000-6830823fa12b40e784a2 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone EI-B (JEOL JMS-01-SG-2) , Positive-QTOF | splash10-0597-7920000000-dde7fba02fcbcec2d665 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone EI-B (HITACHI RMU-6E) , Positive-QTOF | splash10-05fs-4920000000-ccd839134de79f179f9e | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone EI-B (HITACHI M-80) , Positive-QTOF | splash10-00ds-0950000000-48c1f79091d708072f30 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone LC-ESI-ITFT , positive-QTOF | splash10-0a4j-6900000000-3d818ffe03ecd499e078 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone LC-ESI-ITFT , positive-QTOF | splash10-0a4j-7900000000-6db3d23d98d548cbbfaa | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone LC-ESI-ITFT , positive-QTOF | splash10-0ukj-2690000000-14b953cb16c53d1e2744 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone LC-ESI-ITFT , positive-QTOF | splash10-0uka-2790000000-dcd6839af64c3ef6006e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone LC-ESI-ITFT , positive-QTOF | splash10-0006-0090000000-b5f0189f1d6f21b90673 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone LC-ESI-ITFT , positive-QTOF | splash10-0006-0090000000-21e1bde01931b051a4a3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone 30V, Positive-QTOF | splash10-0fe1-0940000000-acd7cb439468ece54d34 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone 50V, Positive-QTOF | splash10-00am-0900000000-9f695ef54b7a75aa0ca5 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone 55V, Positive-QTOF | splash10-0a4j-6900000000-cc148be066f76bf120a2 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone 80V, Positive-QTOF | splash10-0a4j-8900000000-5a1a78a963c17ee2f26b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone 35V, Positive-QTOF | splash10-0ukj-2690000000-075abfa2a19ae84712fb | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone 55V, Positive-QTOF | splash10-0uka-2790000000-528f02372cf3ac228b4a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Testosterone 35V, Positive-QTOF | splash10-052k-7950000000-7505adc1ceff21713130 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone 10V, Positive-QTOF | splash10-00dr-0190000000-4b469479ef097f60ed90 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone 20V, Positive-QTOF | splash10-00dr-0390000000-8bebba5f70c72e80b630 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone 40V, Positive-QTOF | splash10-0udi-5890000000-46ba5a59d051001f2a63 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone 10V, Negative-QTOF | splash10-000i-0090000000-3c963477109db1f6b39e | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone 20V, Negative-QTOF | splash10-000i-0090000000-87d4a2534cd39e8c54a8 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone 40V, Negative-QTOF | splash10-0abc-1190000000-abbd0808a06f67c1f6fc | 2017-07-26 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 500 MHz, CDCl3, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane (predicted from logP)
- Endoplasmic reticulum
|
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Saliva
- Urine
|
---|
Tissue Locations | - Brain
- Ovary
- Semen
- Skeletal Muscle
- Testis
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.00260-0.0139 uM | Newborn (0-30 days old) | Female | Normal | | details | Blood | Detected and Quantified | 0.000693-0.00277 uM | Not Specified | Not Specified | Normal | | details | Blood | Detected and Quantified | 0.0156-0.0347 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.00139 +/- 0.000763 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.00004-0.00215 uM | Children (1-13 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0-0.00098 uM | Children (1-13 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.00036-0.0017 uM | Adolescent (13-18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0-0.000198 uM | Infant (0-1 year old) | Male | Normal | | details | Blood | Detected and Quantified | 0-0.00012 uM | Children (1-13 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0-0.0154 uM | Children (1-13 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.00125-0.0276 uM | Adolescent (13-18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.00125 +/- 0.00042 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.013 (0.0083-0.0286) uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | <0.000400 uM | Not Specified | Both | Normal | | details | Blood | Detected and Quantified | 0.00800 - 0.0400 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.000200 - 0.00300 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.00936 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.0171 +/- 0.00510 uM | Children (1-13 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.0094 +/- 0.0014 uM | Adult (>18 years old) | Male | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00101 (0.00002-0.002) uM | Adult (>18 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00065 +/- 0.00012 uM | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected and Quantified | 0.00120 (0.00108-0.00133) uM | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected and Quantified | 0.000677 (0.000590-0.000764) uM | Adult (>18 years old) | Female | Normal | | details | Saliva | Detected and Quantified | 0.00034 +/- 0.00011 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.00042 +/- 0.00013 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.00033 +/- 0.00014 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.00031 +/- 0.00015 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.00027 +/- 0.00013 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.00028 +/- 0.00013 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.000077 +/- 0.000036 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.000069 +/- 0.000036 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.00037 +/- 0.00016 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.00035 +/- 0.00015 uM | Adult (>18 years old) | Both | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 1.07 +/- 0.19 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | <0.000104 uM | Newborn (0-30 days old) | Female | Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete | | details | Blood | Detected and Quantified | 0.000624-0.0156 uM | Newborn (0-30 days old) | Male | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 9.31 (3.31-19.95) uM | Adult (>18 years old) | Male | Cadmium exposure | | details | Blood | Detected and Quantified | 0.00385 uM | Adult (>18 years old) | Female | 21-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0.00121-0.0118 uM | Adult (>18 years old) | Male | Woodhouse-Sakati syndrome | | details | Blood | Detected and Quantified | 0.00198-0.00368 uM | Adult (>18 years old) | Female | 21-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0.010 +/- 0.013 uM | Adolescent (13-18 years old) | Male | Hypogonadism | | details | Blood | Detected and Quantified | 0.00900-0.0360 uM | Adult (>18 years old) | Male | X-linked ichthyosis | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Prostate cancer | | details | Blood | Detected and Quantified | <0.000140 uM | Adult (>18 years old) | Female | Lipoid Adrenal Hyperplasia | | details | Blood | Detected and Quantified | <0.000140 uM | Adolescent (13-18 years old) | Female | Lipoid Adrenal Hyperplasia | | details | Blood | Detected and Quantified | 0.00243 uM | Adult (>18 years old) | Female | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Schizophrenia | | details | Blood | Detected and Quantified | 0.00150-0.00420 uM | Children (1-13 years old) | Both | 11-beta-hydroxylase deficiency | | details | Blood | Detected and Quantified | <0.000002 uM | Children (1-13 years old) | Female | Aromatase deficiency | | details | Blood | Detected and Quantified | <0.000693 uM | Adolescent (13-18 years old) | Female | Adrenal hyperplasia, congenital, due to 17-alpha-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0.00933 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00184 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00003400 +/- 0.00001665 uM | Adult (>18 years old) | Not Specified | Leuprolide acetate-induced hypogonadism | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.000497 +/- 0.000222 uM | Adult (>18 years old) | Not Specified | Leuprolide acetate-induced hypogonadism with testosterone replacment | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Hypogonadism |
---|
- http://en.wikipedia.org/wiki/Testosterone [Link]
| Cadmium exposure |
---|
- Zeng X, Lin T, Zhou Y, Kong Q: Alterations of serum hormone levels in male workers occupationally exposed to cadmium. J Toxicol Environ Health A. 2002 Apr 12;65(7):513-21. [PubMed:11939709 ]
| Prostate cancer |
---|
- Madu CO, Lu Y: Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77. [PubMed:20975847 ]
| Schizophrenia |
---|
- Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24. [PubMed:22944140 ]
| Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency |
---|
- Hattori N, Ishihara T, Moridera K, Hino M, Ikekubo K, Kurahachi H: A case of late-onset congenital adrenal hyperplasia due to partial 3 beta-hydroxysteroid dehydrogenase deficiency. Endocr J. 1993 Feb;40(1):107-9. [PubMed:7951484 ]
- Benkert AR, Young M, Robinson D, Hendrickson C, Lee PA, Strauss KA: Severe Salt-Losing 3beta-Hydroxysteroid Dehydrogenase Deficiency: Treatment and Outcomes of HSD3B2 c.35G>A Homozygotes. J Clin Endocrinol Metab. 2015 Aug;100(8):E1105-15. doi: 10.1210/jc.2015-2098. Epub 2015 Jun 16. [PubMed:26079780 ]
- Guven A, Polat S: Testicular Adrenal Rest Tumor in Two Brothers with a Novel Mutation in the 3-Beta-Hydroxysteroid Dehydrogenase-2 Gene. J Clin Res Pediatr Endocrinol. 2017 Mar 1;9(1):85-90. doi: 10.4274/jcrpe.3306. Epub 2016 Jul 29. [PubMed:27476613 ]
| 11-beta-Hydroxylase deficiency |
---|
- Burren CP, Montalto J, Yong AB, Batch JA: CYP11 beta 1 (11-beta-hydroxylase) deficiency in congenital adrenal hyperplasia. J Paediatr Child Health. 1996 Oct;32(5):433-8. [PubMed:8933406 ]
| Aromatase deficiency |
---|
- Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H: Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab. 1997 Jun;82(6):1739-45. doi: 10.1210/jcem.82.6.3994. [PubMed:9177373 ]
| 21-Hydroxylase deficiency |
---|
- Warinner SA, Zimmerman D, Thompson GB, Grant CS: Study of three patients with congenital adrenal hyperplasia treated by bilateral adrenalectomy. World J Surg. 2000 Nov;24(11):1347-52. [PubMed:11038205 ]
- Gmyrek GA, New MI, Sosa RE, Poppas DP: Bilateral laparoscopic adrenalectomy as a treatment for classic congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency. Pediatrics. 2002 Feb;109(2):E28. [PubMed:11826238 ]
| Congenital Adrenal Hyperplasia, due to 17-Hydroxylase-Deficiency |
---|
- Wong SL, Shu SG, Tsai CR: Seventeen alpha-hydroxylase deficiency. J Formos Med Assoc. 2006 Feb;105(2):177-81. doi: 10.1016/S0929-6646(09)60342-9. [PubMed:16477341 ]
| Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete |
---|
- Kim CJ, Lin L, Huang N, Quigley CA, AvRuskin TW, Achermann JC, Miller WL: Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab. 2008 Mar;93(3):696-702. doi: 10.1210/jc.2007-2330. Epub 2008 Jan 8. [PubMed:18182448 ]
| Woodhouse-Sakati syndrome |
---|
- Woodhouse NJ, Sakati NA: A syndrome of hypogonadism, alopecia, diabetes mellitus, mental retardation, deafness, and ECG abnormalities. J Med Genet. 1983 Jun;20(3):216-9. [PubMed:6876115 ]
| X-linked ichthyosis |
---|
- Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Moller S, Svenstrup B: Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clin Endocrinol (Oxf). 1985 Oct;23(4):385-93. [PubMed:3864567 ]
| Lipoid Congenital Adrenal Hyperplasia |
---|
- Fujieda K, Tajima T, Nakae J, Sageshima S, Tachibana K, Suwa S, Sugawara T, Strauss JF 3rd: Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest. 1997 Mar 15;99(6):1265-71. doi: 10.1172/JCI119284. [PubMed:9077535 ]
|
|
---|
Associated OMIM IDs | - 146110 (Hypogonadism)
- 176807 (Prostate cancer)
- 181500 (Schizophrenia)
- 201810 (Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency)
- 202010 (11-beta-Hydroxylase deficiency)
- 613546 (Aromatase deficiency)
- 201910 (21-Hydroxylase deficiency)
- 202110 (Congenital Adrenal Hyperplasia, due to 17-Hydroxylase-Deficiency)
- 613743 (Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete)
- 241080 (Woodhouse-Sakati syndrome)
- 308100 (X-linked ichthyosis)
- 201710 (Lipoid Congenital Adrenal Hyperplasia)
|
---|
External Links |
---|
DrugBank ID | DB00624 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | C00003675 |
---|
Chemspider ID | 5791 |
---|
KEGG Compound ID | C00535 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Testosterone |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 6013 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 17347 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | TSTSTERONE |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Ercoli, Alberto; De Ruggieri, Pietro. An improved method of preparing testosterone, dihydrotestosterone, and some of their esters. Journal of the American Chemical Society (1953), 75 650-3. |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Kim YS, Zhang H, Kim HY: Profiling neurosteroids in cerebrospinal fluids and plasma by gas chromatography/electron capture negative chemical ionization mass spectrometry. Anal Biochem. 2000 Jan 15;277(2):187-95. [PubMed:10625505 ]
- Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, Paolino S, Seriolo B, Felli L, Straub RH: Anti-TNF and sex hormones. Ann N Y Acad Sci. 2006 Jun;1069:391-400. [PubMed:16855166 ]
- Schwarz S, Pohl P: Steroid hormones and steroid hormone binding globulins in cerebrospinal fluid studied in individuals with intact and with disturbed blood-cerebrospinal fluid barrier. Neuroendocrinology. 1992 Feb;55(2):174-82. [PubMed:1620285 ]
- Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, Gooren LJ, Lips P: The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf). 2005 Aug;63(2):152-60. [PubMed:16060908 ]
- Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR: Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause. 2006 May-Jun;13(3):528-37. [PubMed:16735951 ]
- Handelsman DJ: Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab. 2006 May;91(5):1646-53. Epub 2006 Feb 14. [PubMed:16478815 ]
- Duschek EJ, Gooren LJ, Netelenbos C: Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas. 2005 Jul 16;51(3):286-93. [PubMed:15978972 ]
- Huang I, Jones J, Khorram O: Human seminal plasma nitric oxide: correlation with sperm morphology and testosterone. Med Sci Monit. 2006 Mar;12(3):CR103-6. Epub 2006 Feb 23. [PubMed:16501419 ]
- Hussein A, Ozgok Y, Ross L, Niederberger C: Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl. 2005 Nov-Dec;26(6):787-91; discussion 792-3. [PubMed:16291975 ]
- Ahtiainen JP, Pakarinen A, Alen M, Kraemer WJ, Hakkinen K: Short vs. long rest period between the sets in hypertrophic resistance training: influence on muscle strength, size, and hormonal adaptations in trained men. J Strength Cond Res. 2005 Aug;19(3):572-82. [PubMed:16095405 ]
- Landman AD, Sanford LM, Howland BE, Dawes C, Pritchard ET: Testosterone in human saliva. Experientia. 1976;32(7):940-1. [PubMed:954994 ]
- Knickmeyer RC, Wheelwright S, Taylor K, Raggatt P, Hackett G, Baron-Cohen S: Gender-typed play and amniotic testosterone. Dev Psychol. 2005 May;41(3):517-28. [PubMed:15910159 ]
- Fejes I, Koloszar S, Szollosi J, Zavaczki Z, Pal A: Is semen quality affected by male body fat distribution? Andrologia. 2005 Oct;37(5):155-9. [PubMed:16266392 ]
- Jarow JP, Zirkin BR: The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci. 2005 Dec;1061:208-20. [PubMed:16467270 ]
- Rovensky J, Radikova Z, Imrich R, Greguska O, Vigas M, Macho L: Gonadal and adrenal steroid hormones in plasma and synovial fluid of patients with rheumatoid arthritis. Endocr Regul. 2004 Dec;38(4):143-9. [PubMed:15841793 ]
- Klimek M, Pabian W, Tomaszewska B, Kolodziejczyk J: Levels of plasma ACTH in men from infertile couples. Neuro Endocrinol Lett. 2005 Aug;26(4):347-50. [PubMed:16136011 ]
- Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR: Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14-28;166(15):1660-5. [PubMed:16908801 ]
- Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010. Epub 2006 May 23. [PubMed:16720669 ]
- Jarow JP, Wright WW, Brown TR, Yan X, Zirkin BR: Bioactivity of androgens within the testes and serum of normal men. J Androl. 2005 May-Jun;26(3):343-8. [PubMed:15867001 ]
- Bridger T, MacDonald S, Baltzer F, Rodd C: Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006 Mar;160(3):241-6. [PubMed:16520442 ]
- Kazi M, Geraci SA, Koch CA: Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med. 2007 Oct;120(10):835-40. [PubMed:17904450 ]
- Krone N, Hanley NA, Arlt W: Age-specific changes in sex steroid biosynthesis and sex development. Best Pract Res Clin Endocrinol Metab. 2007 Sep;21(3):393-401. [PubMed:17875487 ]
- Authors unspecified: Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990 Oct 20;336(8721):955-9. [PubMed:1977002 ]
- Hoberman JM, Yesalis CE: The history of synthetic testosterone. Sci Am. 1995 Feb;272(2):76-81. [PubMed:7817189 ]
- Freeman ER, Bloom DA, McGuire EJ: A brief history of testosterone. J Urol. 2001 Feb;165(2):371-3. [PubMed:11176375 ]
|
---|